The story focuses on a recent paper published in the journal Breast Cancer Research, which addresses breast cancer risk and regular use of aspirin in low doses. The story notes that regular use of low doses of aspirin may reduce the risk of breast cancer in women. Or it may not, we would like to add.
That’s an important qualifier, since it is impossible to know whether the aspirin affected breast cancer risk based on this study. That’s because this was an observational study — meaning that it could detect a correlation between aspirin use and breast cancer, but not whether the use of aspirin was actually responsible for lower rates of breast cancer. That’s a key distinction, and we wish the story had explained it explicitly. That said, this story addresses the issue more successfully than a related news release, which we reviewed earlier. The story also does a better job of addressing potential harms.
As we noted in our review of the related news release, breast cancer is the second most common type of cancer-related death among women in the United States and is diagnosed in hundreds of thousands of women each year. That means many thousands — if not millions — of women and their loved ones are on the lookout for things they can do to reduce their risk of developing breast cancer. If ever there is a time to delve into details, such as how other steps women can take to reduce their risk, or how this fits into the existing body of work on aspirin and reducing cancer risk, this would seem to be it. But news stories should take pains to spell out limitations of research and not overstate what a study found.
Cost isn’t mentioned. This may be because the story assumes the public knows that low-dose aspirin is inexpensive (a year’s supply would likely be less than $20). It’s good to make that clear, but because of the minimal cost will rate it N/A.
The story makes the same mistake here that the news release did, sharing only relative risk reduction numbers — not the actual numbers of people who reduced their risk of breast cancer by taking aspirin. In addition, the story would have been stronger if it had explained that observational studies, like this one, cannot determine whether a specific intervention (i.e., aspirin use) was responsible for reducing cancer risk.
The story notes that aspirin can increase risk for internal bleeding, and says that women should consult a doctor before beginning a daily-aspirin regimen. This is satisfactory–but barely–since the magnitude of this potential harm is not mentioned.
As noted above and in our review of the news release, observational studies like this one can only identify correlations. These studies can’t prove a causal relationship — i.e., that the action (taking aspirin) caused the result (reduced risk of breast cancer). The story does not address that head on. The story also doesn’t address whether other factors — such as age or weight — may have contributed to the difference in breast cancer rates. The story does, however, address hormone therapy and alcohol use among study participants, and explains why those factors are important. That’s a plus. Lastly, the story notes that most of the study participants were white, but doesn’t explain to readers why that is relevant.
Another omission in the story is that more than 4,100 women who had developed breast cancer before the 10-year follow-up were excluded from the study. This should have been mentioned as a limitation. We wonder how these women who were excluded differed in their low-dose aspirin intake from those who developed breast cancer later on.
The story doesn’t note who funded the research, nor does it incorporate input from independent sources.
There are a host of things that women can do to reduce their risk of breast cancer, though all of it’s based on observational data, and aren’t powered to prove that reducing the behavior actually reduces breast cancer. There should have been at least some discussion about these factors.
Low-dose aspirin is already widely available and is used by many women to reduce their risk of cardiovascular disease.
It’s not clear from the story what is novel about this study. A reader who searches online for related material may run across this news release from the American Cancer Society on aspirin use and colorectal cancer. Is this different because of the type of cancer? Because of the dose of aspirin? Both? It’s always good to help readers place new findings in context, and often dicey to assume that readers will automatically understand how the new findings fit into the broader research on the topic.
As the news release explained: “This study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.”
The story contained information about the harms of aspirin, which was not in the news release, which we reviewed. This is a barely passing satisfactory since the story mostly otherwise uses information from the release, but at least not verbatim.
Systematic, Criteria-Driven
More for milk debates: "Switching to skim #milk may slow biological aging" https://upi.com/6975065t via @upi cc @garyschwitzer @joansalgeblake
"We can't say that this was caused by milk fat." As is often the case with nutrition studies: correlation ≠ causation.
#RelaxDammit
@HealthNewsRevu @mcjaklevic HealthNewsReview once again revealing hype that far outstrips reality. I suspect that one day, AI will meaningfully contribute to good patient care. Whether that's in 10 years or 100, I couldn't say. What is clear is that we ain't there yet.
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like